C-suite level selling totaling over half a million dollars raises concerns about confidence in near-term valuation, especially following option exercises. Traders should watch for changes in forward guidance or upcoming clinical trial data that may have influenced timing. Monitor next 10-Q for potential revenue or pipeline updates.
Price Chart
Executive Summary
Bicara Therapeutics executives Claire Mazumdar (CEO) and Ryan Cohlhepp (President/COO) sold a combined $538,203 worth of shares in open-market transactions over a 6-day window. These sales follow derivative exercises and represent material insider selling by two top executives.
Key Financial Metrics
Key Facts
- CEO Claire Mazumdar sold 15,000 shares for $354,145.50 on April 20, 2026, following multiple derivative exercises.
- President and COO Ryan Cohlhepp sold 8,000 shares for $184,058.40 on April 15, 2026, after exercising derivatives.
- Total open-market sales in the cluster amount to $538,203, representing approximately 0.034% of the company's $1.6B market cap.
- Both executives exercised in-the-money options prior to selling, with some transactions involving non-cash exercises (code M).
Financial Impact
$538,203 in open-market sales by C-suite executives
Risk Factors
- Perception of insider pessimism despite non-cash exercises being routine
- Potential for negative market reaction due to concentrated selling by top leadership
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-BCAX-1776727656831 |
Track record builds as more directional reports settle.
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Aug 25, 2026 5w ago | 8-K | $24.73 $19.78 | ▼ −20.02% | ▼ −20.24% | $18.25 (−26.18%) |
Aug 14, 2026 7w ago | Press Release | $24.28 $23.20 | ▼ −4.45% | ▼ −2.46% | $18.25 (−24.81%) |
Aug 12, 2026 7w ago | Insider Cluster | $23.63 $22.81 | ▼ −3.47% | ▼ −1.72% | $18.25 (−22.75%) |
Aug 12, 2026 7w ago | Insider Cluster | $23.63 $22.81 | ▼ −3.47% | ▼ −1.72% | $18.25 (−22.75%) |
Aug 11, 2026 7w ago | 8-K | $23.76 $23.64 | ▼ −0.51% | ▲ +0.55% | $18.25 (−23.17%) |
Aug 11, 2026 7w ago | Press Release | $23.76 $23.64 | ▼ −0.51% | ▲ +0.55% | $18.25 (−23.17%) |
Jul 14, 2026 11w ago | Insider Cluster | $28.10 $23.76 | ▼ −15.44% | ▼ −17.94% | $18.25 (−35.04%) |
Jun 11, 2026 16w ago | Institutional Cluster | $21.28 $29.68 | ▼ −39.47% | ▼ −37.58% | $18.25 (+14.22%) |
May 26, 2026 18w ago | Insider Cluster | $21.58 $26.34 | ▲ +22.06% | ▲ +23.96% | $18.25 (−15.41%) |
May 11, 2026 20w ago | 8-K | $22.92 $20.56 | ▼ −10.30% | ▼ −9.99% | $18.25 (−20.35%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Try SecBot Free Coming soon: SecBot Pro with alerts, watchlists, and API access